No Data
No Data
Morgan Stanley Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Cuts Target Price to $195
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Delivered A Weaker ROE Than Its Industry
Little Excitement Around Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Revenues
H.C. Wainwright Maintains Sarepta Therapeutics(SRPT.US) With Sell Rating, Maintains Target Price $75
A Quick Look at Today's Ratings for Sarepta Therapeutics(SRPT.US), With a Forecast Between $75 to $217
Express News | HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $75 Price Target